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Abstract
Background: Inflammatory arthritides including rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing
spondylitis (AS) are associated with increased risk of cardiovascular disease. This process may be driven by systemic
inflammation, and the use of tumour necrosis factor (TNF) inhibitors could therefore potentially reduce cardiovascular
risk by reducing this inflammatory burden. The aims of this study were to evaluate whether the risk of cardiovascular
events (CVEs) in patients with inflammatory arthritis is associated with treatment with anti-TNF therapy, compared with
other biologics or non-biologic therapy, and to compare the CVE risk between participants with RA, PsA and AS.
Methods: Data from consecutive participants in the Australian Rheumatology Association Database with RA, PsA and
AS from September 2001 to January 2015 were included in the study. The Cox proportional hazards model using the
counting process with time-varying covariates tested for risk of having CVEs, defined as angina, myocardial infarction,
coronary artery bypass graft, percutaneous coronary intervention, other heart disease, stroke/transient ischaemic attack
or death from cardiovascular causes. The model was adjusted for age, sex, diagnosis, methotrexate use, prednisone use,
non-steroidal anti-inflammatory use, smoking, alcohol consumption, hypertension, hyperlipidaemia, diabetes and
functional status (Health Assessment Questionnaire Disability Score).
Results: There were 4140 patients included in the analysis, totalling 19,627 patient-years. After multivariate adjustment,
the CVE risk was reduced with anti-TNF use (HR 0.85, 95% CI 0.76–0.95) or other biologic therapies (HR 0.81, 95%
CI 0.70–0.95), but not in those who had ceased biologic therapy (HR 0.96, 95% CI 0.83–1.11). After adjustment, no
significant difference in CVE risk was observed between participants with RA and PsA (HR 0.92, 95% CI 0.77–1.10)
or AS (HR 1.14, 95% CI 0.96–1.36).
Conclusions: Current biologic use was associated with a reduction in major CVEs. No reduction in CVE risk was
seen in those who had ceased biologic therapy. After adjustment, the CVE risk was not significantly different
between RA, AS or PsA.
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Background
Inflammatory arthritides such as rheumatoid arthritis
(RA), ankylosing spondylitis (AS) and psoriatic arthritis
(PsA) impose a heavy burden of morbidity and mortality
on populations worldwide. A significant component of
this is the two-fold increased risk of cardiovascular
events (CVEs) [1], with some evidence for increasing
risk with longer disease duration [2–4]. It has been pro-
posed that this is due to inflammatory processes driven
by cytokines such as tumour necrosis factor (TNF), with
a high inflammatory burden driving autoantibody pro-
duction and apoptosis of endothelial cells to cause vas-
cular damage [5] and a pro-thrombotic state [6].
The use of TNF inhibitors could therefore potentially re-
duce cardiovascular risk by controlling systemic inflamma-
tion. A recent study demonstrated that an RA cohort with
disease onset after the year 2000 did not have an increased
mortality risk compared to the general population, whereas
those with disease onset prior to 2000 were at increased
risk [7]. Several studies have demonstrated that treatment
of inflammatory arthritis with TNF inhibitors is associated
with an improvement in surrogate markers of cardiovascu-
lar health such as endothelial stiffness, biochemical lipid
profile and carotid intima-media thickness [8–13].
There is conflicting evidence regarding clinical cardio-
vascular endpoints such as rate of myocardial infarction,
stroke and cardiovascular-related death after treatment
with biologics in patients with RA. Some studies report
a lower risk of CVEs [14, 15], while others report no sig-
nificant difference [16, 17]. Studies assessing cardiovas-
cular risk in RA have been performed in locations
including North America [14, 18, 19], Britain [20] and
Sweden [21], but as yet no studies have been undertaken
in the Australian context where there are stringent cri-
teria for accessing biologic therapy. Furthermore, little
research has been done to establish the effect of bio-
logics on the CVE rate for inflammatory arthritis apart
from RA. Thus, wider research is warranted in a range
of arthritic conditions to examine whether biologic ther-
apy is helpful beyond direct arthritic control in these
patients.
The aim of this study was to determine whether the
risk of CVEs in patients with RA, AS or PsA was associ-
ated with treatment with anti-TNF therapy, compared
with other biologics or non-biologic therapy, and to
compare the CVE risk between arthritis diagnoses.
Methods
The Australian Rheumatology Association Database (ARAD)
is a national voluntary registry for patients with inflammatory
arthritis (RA, AS, PsA and juvenile idiopathic arthritis).
Details regarding the ARAD methodology have been
described previously [22]. Briefly, participants with in-
flammatory arthritis complete self-reported questionnaires
in paper or online format. Initially, these were com-
pleted biannually; however, from January 2014, the fre-
quency of questionnaires was decreased to annually
after the first 2 years of follow-up. The participant ques-
tionnaires include self-reported demographic details,
current and past use of medications for arthritis, and
current and past co-morbid medical conditions. Partici-
pants also complete patient-reported outcome measures
including the Health Assessment Questionnaire Disability
Score (HAQ)—a measure of functional status with scores
ranging from 0 to 3 where higher scores indicate greater
disability [23].
The majority of participants are referred by their treat-
ing rheumatologist (98.5%) and a small proportion is
self-referred. Rheumatologists complete basic informa-
tion at baseline including demographics and diagnosis.
Cause of death is validated by data linkage to the Aus-
tralian National Death Index, which provides verified
International Statistical Classification of Diseases and
Related Health Problems, 10th revision (ICD-10) coding
for cause of death [24]. Skilled data-entry personnel re-
view inputs and correct errors, contacting participants
for clarification as required.
Consecutive participants with RA, PsA or AS who had
completed at least two separate ARAD question-
naires from database inception on 12 September 2001 to
28 January 2015 were included in the analysis. Demo-
graphic details, diagnosis, date of questionnaire, medica-
tions, medical history, HAQ score and, when applicable,
cause of death were extracted from the ARAD on 28
January 2015. The primary outcome of interest was the
composite rate of CVEs. CVEs were defined as any
stable/unstable angina, myocardial infarction, coronary
artery bypass graft, percutaneous coronary intervention,
other heart disease (e.g. valvular), stroke/transient is-
chaemic attack or death from cardiovascular causes.
This was in line with definitions commonly used in the
literature [25–28]. Identification of CVEs, other than
cardiovascular-related death, was based upon partici-
pants’ self-report. Based on ICD-10 codes obtained via
data linkage with the Australian National Death Index,
any cause of death in Chapter IX (Blocks I00–I99, “Dis-
eases of the circulatory system”) was identified as a
cardiovascular-related death and included in the com-
posite measure of CVEs [24, 29].
Statistical methods
Survival analysis was conducted in SAS 9.4 using the Cox
proportional hazards model and the counting process
method to estimate hazard ratios (HRs) and correspond-
ing 95% confidence intervals (95% CIs) for the rate of
CVEs in patients who had anti-TNF biologic treatment, as
compared to those with other biologic therapy or no bio-
logic therapy. A repeated-events counting process model
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was utilised rather than a time-to-first-event model in order
to account for the increased risk from multiple events dur-
ing follow-up [30–32]. Participants who did not experience
any CVE were right censored at the end of follow-up.
The main predictor of interest was biologic therapy use.
The ARAD codes individual biologic therapies as current,
previous, never or unknown, at each reported time point.
For this analysis, biologic therapies were coded by confla-
tion into anti-TNF (infliximab, etanercept, adalimumab,
golimumab, certolizumab pegol) or other (anakinra, ritux-
imab, abatacept, tocilizumab) to form the mutually exclu-
sive groups of current anti-TNF use, current other
biologic use, previous biologic use (any) or biologic-naïve.
Data points where participants reported unknown biologic
use were treated as missing and were excluded from the
analysis. Medication use was coded as a time-varying vari-
able to account for participants being put on different
treatment across the longitudinal cohort study. Included
participants were assumed to continue their reported bio-
logic therapy for the interval between surveys.
Other participant characteristics included in the model
as explanatory variables were age, sex, arthritis diagnosis,
disease duration, alcohol usage and smoking status.
Treatment status for non-steroidal anti-inflammatory
drugs (NSAIDs), methotrexate and prednisone/prednis-
olone was coded as never, current, past or unknown.
Co-morbid medical illnesses which are known cardiac
risk factors (hyperlipidaemia, hypertension or diabetes)
were also included as explanatory variables. These were
self-reported in the ARAD as current, past, never or un-
known. Those that were reported as current or past
were coded as a positive history while those reported as
never were coded as negative. Data points where partici-
pants reported an unknown history were treated as miss-
ing data and dropped from the analysis. The HAQ was
included as a continuous variable. Univariate analyses
were conducted and continuous variables were checked
for linearity. Variables with a p value less than 0.25 in the
univariate analysis were included in the multivariate
model. Multi-collinearity in the multivariate model was
evaluated using variance inflation factors (VIFs).
Multivariate analysis was performed using the back-
wards elimination method and the χ2 likelihood ratio test.
Hazard ratios (HRs) with 95% confidence intervals (95%
CIs) were reported using an α value of 0.05. The risk of
CVEs was compared between RA, AS and PsA using the
HR for each diagnosis from the final adjusted multivariate
model. The results were reported in accordance with the
“Strengthening the Reporting of Observational Studies in
Epidemiology” (STROBE) guidelines [33].
Results
Between 2001 and 2015, there were 4787 participants
enrolled in the ARAD with a diagnosis of RA, AS or
PsA (Fig. 1). Participants with only a single completed
questionnaire (n = 647) were excluded. Thus, 4140 par-
ticipants were included in the analysis, totalling 32,844
completed questionnaires. Participant demographics at
the time of enrolment in the ARAD are presented in
Table 1. The median age was 56 years (interquartile
range (IQR) 46–64 years), and 33.6% were male. The
majority of participants had a diagnosis of RA (n = 3167,
76.5%), 561 (13.6%) had AS and 412 (10.0%) had PsA.
The median time since diagnosis was 10 years (IQR 4–
19 years) and the median (IQR) HAQ was 1.13 (0.50–
1.75). Participants who had ever smoked regularly com-
prised 37.2% of the sample. In terms of alcohol use,
13.2% of participants were daily users, 54.4% occasional
users and 32.4% non-users. Self-reported co-morbidities
included hypertension (34.9%), hyperlipidaemia (19.1%)
and diabetes (7.6%).
Table 2 presents disease-modifying anti-rheumatic
drug (DMARD) use at the time of enrolment in the
ARAD: the majority of participants were recruited on
current anti-TNF biologic therapy (56.8%), with some on
alternative biologics (3.1%), and 36.8% of participants
were biologic-naïve at ARAD enrolment. At baseline,
1776 (56.3%) participants with RA, 265 (64.5%) partici-
pants with PsA and 437 (78.0%) participants with AS
were taking a biologic therapy. Current methotrexate
use was reported by 55.6% of participants at enrolment,
39.0% were currently taking prednisone or prednisolone
and 51.4% were currently taking NSAIDs.
The study period comprised a total of 19,627
patient-years. Therapy was primarily anti-TNF (12,555
patient-years, 64.0%) or other biologics (1963 patient-years,
10.1%), while 10.0% (1955 patient-years) had ceased bio-
logic therapy and 15.9% (3116 patient-years) were biolo-
gic-naïve. Only 29 patient-years (0.1%) included
unknown DMARD therapy. Across the study period,
552 participants (13.3%) experienced a composite car-
diac event and 10 died secondary to cardiovascular
causes, with only one of these 10 participants report-
ing a CVE during the study period before dying of a
cardiovascular cause.
Univariate Cox proportional hazards regression analyses
for the whole group showed that increased age, male gen-
der, RA diagnosis, disease duration, greater disability
(higher HAQ), ever smoking regularly, ever using metho-
trexate, current prednisone/prednisolone or NSAIDs, or a
medical history of hypertension, hyperlipidaemia and dia-
betes were all significant predictors of CVEs at the 0.25
level of significance (Table 3). Use of biologic therapy, past
but not current use of prednisone/prednisolone and any
level of alcohol use were inversely associated with CVEs.
Continuous variables of age and disease duration were
evaluated for linearity, and there was no evidence of
multi-collinearity.
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Multivariate analysis for the whole group (Table 4)
found that, following adjustment for potential con-
founders, compared to the biologic-naïve, the CVE risk
was reduced with anti-TNF use (HR 0.85, 95% CI 0.76–
0.95) as well as use of other biologic therapies (HR 0.81,
95% CI 0.70–0.95), but was not reduced when biologic
use was ceased (HR 0.96, 95% CI 0.83–1.11). After ad-
justment, no significant difference in the CVE rate was
observed between RA and PsA (HR 0.92, 95% CI 0.77–
1.10) or AS (HR 1.14, 95% CI 0.96–1.36). Co-morbid
hypertension, hyperlipidaemia and diabetes were all sig-
nificant positive predictors of major adverse CVEs, as
were increased age, male sex, ever smoking regularly,
greater disability (higher HAQ) and current treatment
with methotrexate or current use of NSAIDs. Alcohol
use was associated with a decreased risk of CVEs. After
adjusting for other variables, disease duration was not a
significant predictor of major adverse CVEs.
Discussion
This study has demonstrated a reduction in CVEs associ-
ated with biologic use for both anti-TNF and other bio-
logic agents in ARAD participants with RA, PsA or AS,
compared with ARAD participants who were
biologic-naïve. However, this protective effect for the CVE
rate was not observed in those who had ceased using bio-
logic agents. Previous studies have shown that people with
any inflammatory arthritis have increased rates of both
cardiovascular morbidity and cardiovascular mortality
compared to the general population [4, 34–36]. However,
there are few primary studies directly comparing event
rates between different forms of inflammatory arthritis.
Our study explored the relationship between anti-TNF
use and CVEs in the Australian context and was also
able to examine three different types of inflammatory
arthritis in the same cohort. A reduced risk of myocar-
dial infarction for RA patients treated with anti-TNF
agents compared with conventional DMARDs was also
reported in a recently updated analysis of the British So-
ciety for Rheumatology Biologic Register (BSRBR-RA)
[37]. The baseline characteristics of patients entered in
the ARAD are similar to the biologic-exposed popula-
tion in the BSRBR-RA [20]. A similar reduction in acute
coronary syndrome events for patients with RA using
anti-TNF therapy was also found in a recent Swedish co-
hort study [38]. A recent systematic review reported a
decreased risk of CVEs in patients with RA treated with
TNF inhibitors or with methotrexate, and an increased
risk in those using glucocorticoids or NSAIDs [39]. This
review also reported that treatment with systemic ther-
apy decreased the risk of CVEs in patients with PsA or
psoriasis. However, there was insufficient data to com-
pare the CVE risk between individual therapies.
In the multivariate model, while current methotrexate
use was not associated with any difference in CVE risk,
those who had ceased methotrexate had an increased
risk of CVEs compared to those who had never taken
the medication. Conversely, participants who had ceased
taking prednisone or prednisolone were at lower risk of
CVEs compared with those who had never taken pred-
nisone. The reasons for these associations are unclear,
but there may be confounding by indication for these
medications. There may also be confounders which are
not accounted for, including socioeconomic factors
which may influence the prescription of different therap-
ies, or some associations may have occurred by chance.
Strengths of this study include the large database of
prospective longitudinal data, which was fully utilised
Fig. 1 Flow diagram for participant inclusion from the ARAD. ARAD Australian Rheumatology Association Database, AS ankylosing spondylitis, PsA
psoriatic arthritis, RA rheumatoid arthritis
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with the counting process method of survival analysis
which counts multiple events, and contrasts with the
time-to-first-event analyses which has been used in pre-
vious studies [17, 35, 40]. Our study also had a moderate
mean follow-up time of 5 years, and made a direct com-
parison between several forms of inflammatory arthritis.
Additionally, the continual reporting of participant bio-
logic use at each questionnaire significantly reduced the
potential for misclassification bias.
This article also has some limitations due to the type
of study and the structure of the database. This is an ob-
servational cohort study with the choice of therapy being
made by the rheumatologists and patients, and as such
is only able to show an association and not causation.
Therefore, there are two possible explanations for the re-
duction in the CVE rate. There may be an intrinsic
causative benefit of biologic therapy theoretically due to
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anti-inflammatory properties. Alternatively, it may be due
to selection bias or bias by indication: rheumatologists
choose to prescribe biologics for healthier patients, or to
patients with higher levels of education or socioeco-
nomic status who are consequently at lower risk of car-
diovascular disease. While it is possible that patients
with higher levels of co-morbidities may not have been
offered biologics given higher thresholds for general
health before treatment, patients that qualify for subsidy
under the Australian Pharmaceutical Benefits Scheme
must have more severe or resistant disease—overall, the
net direction of any bias is therefore unclear [22]. Fur-
thermore, disease activity measures such as active joint
counts or inflammatory markers are not collected in the
ARAD. It was therefore not possible to account for dis-
ease activity in this analysis and it is possible that it is
tighter disease control achieved by biologic therapy
which led to a reduction of CVEs, rather than an intrin-
sic effect of the biologics themselves acting on vascular
inflammation.
There were only 10 deaths from cardiovascular causes
observed in our study, which is lower than that which
might be expected from the general Australian popula-
tion. The rate of cardiovascular death in Australia in
2015 was 151 per 100,000 persons [41]. Therefore, ap-
proximately 30 deaths might have been expected in our
study which included a total of 19,627 patient-years of
follow-up. This low mortality rate may reflect a recruit-
ment bias in the ARAD—most participants are Cauca-
sian and speak English as their first language, and
approximately one third have a tertiary-level education.
Higher socioeconomic status and education levels are
associated with reduced risk of cardiovascular death.
Table 2 DMARD usage at ARAD enrolment (n = 4140)
Number Percentage
Biologic use
Never taken 1525 36.8
Currently taking anti-TNF biologics 2350 56.8





Previous use 121 2.9
Unknowna 16 0.4
Methotrexate status
Never taken 977 23.6
Currently taking 2302 55.6
Stopped taking 856 20.7
Unknowna 5 0.1
Prednisone/prednisolone status
Never taken 1529 36.9
Currently taking 1613 39.0
Stopped taking 969 23.4
Unknowna 29 0.7
NSAID status
Not currently taking 2011 48.6
Currently taking 2129 51.4
ARAD Australian Rheumatology Association Database, DMARD disease-
modifying anti-rheumatic drug, TNF tumour necrosis factor, NSAID non-
steroidal anti-inflammatory drug
aParticipant reports that they do not know, or are unsure of the answer
Table 3 Unadjusted univariate Cox proportional hazards
regression for factors predicting cardiovascular events in
patients with inflammatory arthritis (n = 4140)
Factor HR 95% CI p value
Increased age (years) 1.05 1.06–1.07 < 0.0001
Greater disease duration (years) 1.02 1.02–1.02 < 0.0001
Sex (males vs females) 1.44 1.33–1.55 < 0.0001
Biologic use (referent: biologic naïve) < 0.0001
Current TNF biologics 0.63 0.58–0.70 < 0.0001
Current other biologics 0.69 0.60–0.80 < 0.0001
Stopped taking biologics 0.97 0.85–1.10 0.59
Diagnosis (referent: rheumatoid arthritis) < 0.0001
Ankylosing spondylitis 0.61 0.53–0.70 < 0.0001
Psoriatic arthritis 0.75 0.64–0.88 0.0004
Methotrexate treatment (referent: never) < 0.0001
Currently taking methotrexate 1.37 1.18–1.59 < 0.0001
Stopped taking methotrexate 1.56 1.34–1.82 < 0.0001
Prednisone/prednisolone treatment (referent: never) < 0.0001
Currently taking prednisone 1.35 1.22–1.49 < 0.0001
Stopped taking prednisone 0.85 0.76–0.95 0.003
NSAID treatment vs not currently taking 1.19 1.10–1.28 < 0.0001
Smoking regularly ever 1.50 1.39–1.62 < 0.0001
Alcohol use (referent: never) < 0.0001
Sometimes 0.64 0.59–0.69 < 0.0001
Every day 0.85 0.76–0.95 0.01
Hypertension (referent: no) < 0.0001
Positive history for hypertension 2.21 2.04–2.41 < 0.0001
Hyperlipidaemia (referent: no) < 0.0001
Positive history for hyperlipidaemia 2.39 2.22–2.59 < 0.0001
Diabetes (referent: no) < 0.0001
Positive history for diabetes 1.98 1.80–2.18 < 0.0001
Higher HAQa 1.83 1.74–1.92 < 0.0001
HR hazard ratio, CI confidence interval, HAQ Health Assessment Questionnaire
Disability Score, NSAID non-steroidal anti-inflammatory drug, TNF tumour
necrosis factor
aRange 0–3, where higher scores indicate greater functional impairment
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The results may not be generalisable to the broader
population with these conditions.
Apart from cardiovascular death, in this study CVEs
were identified through participant self-report and it is
possible that there was under-reporting of events. It is not
possible to directly compare the incidence of CVEs in our
study with data for the general population in Australia
due to differences in the definitions of CVEs used in the
Australian Institute of Health and Welfare (AIHW) ana-
lysis of the AIHW National Hospital Morbidity Database
and AIHW National Mortality Database [41].
The majority of ARAD participants have RA. The ARAD
was founded in 2001 for the purpose of monitoring the
benefits and safety of new therapies, particularly biologics.
At that time in Australia, biologics were only subsidised by
the Pharmaceutical Benefits Scheme for RA, so these
patients made up the bulk of initial recruitment until bio-
logics were subsidised for AS in 2004 and PsA in 2006
[22]. However, this should not materially affect the ana-
lysis, as comparison is between biologic therapies and
biologic-naïve patients. We did not find any difference in
the CVE risk between RA, PsA and AS, after adjustment
for other risk factors. However, as the number of partici-
pants with PsA and AS is small relative to the number of
RA participants, a false negative finding is possible. The
prevalence of biologics use in the ARAD population is
higher than would be expected for the Australian popula-
tion of patients with these rheumatic diseases. This likely
reflects recruitment bias as patients commencing biologic
therapy were targeted in the early recruitment process.
Furthermore, we used a composite measure for bio-
logic use due to the small numbers of patients treated
with each individual agent. It was therefore not possible
to ascertain whether there was any difference in the
CVE risk between individual biologic therapies. Al-
though the ARAD collects information on reasons for
biologic cessation, it was difficult to isolate a single cause
to explain the finding that the CVE risk in the group
who had ceased using biologic agents was not signifi-
cantly different from the biologic-naïve group. This
could be because those who had ceased biologic therapy
were generally resistant to biologic therapy and thus did
not derive any improvement in either disease status or
the CVE rate, or it could be because any protective ef-
fect from biologic use is not sustained after biologic ces-
sation and participants returned to their previous level
of cardiovascular risk. Medication use was self-reported
and dosages of glucocorticoid and DMARDs were not
collected. Furthermore, some participants reported they
were unsure if they had certain medical conditions, or
had taken some medications. However, this made up
only a small proportion of data points, and is unlikely to
have affected the overall results.
Conclusions
Current use of biologics, whether anti-TNF or another
mechanism of action, is associated with a reduction in
the CVE rate compared to the rate among people with
inflammatory arthritis who are biologic-naïve. This
event reduction was no longer observed in those who
had ceased biologic use. There was no difference in the
CVE risk between RA, PsA and AS. These findings
support the hypothesis that control of systemic inflam-
mation in these conditions may reduce the cardiovas-
cular risk.
Table 4 Multivariate Cox proportional hazards regression for
factors predicting cardiovascular events in patients with
inflammatory arthritis (n = 4140)
Factor HR 95% CI p value
Increased age (years) 1.05 1.05–1.06 < 0.0001
Sex (males vs females) 1.72 1.57–1.88 < 0.0001
Biologic use (referent: biologic naïve) 0.006
Current TNF biologics 0.85 0.76–0.95
Current other biologics 0.81 0.70–0.95
Stopped taking biologics 0.96 0.83–1.11
Diagnosis (referent: rheumatoid arthritis) 0.18
Ankylosing spondylitis 1.14 0.96–1.36
Psoriatic arthritis 0.92 0.77–1.10
Methotrexate treatment (referent: never) 0.0001
Currently taking methotrexate 1.08 0.90–1.29
Stopped taking methotrexate 1.28 1.07–1.53







NSAID treatment vs not currently
taking
1.22 1.13–1.32 < 0.0001
Smoking regularly ever 1.17 1.07–1.27 0.0003
Alcohol use (referent: never) < 0.0001
Sometimes 0.77 0.70–0.84
Everyday 0.77 0.68–0.87
Hypertension (referent: no) < 0.0001
Positive history for hypertension 1.27 1.16–1.39
Hyperlipidaemia (referent: no) < 0.0001
Positive history for hyperlipidaemia 1.65 1.52–1.80
Diabetes (referent: no) < 0.0001
Positive history for diabetes 1.28 1.16–1.42
Higher HAQa 1.48 1.40–1.57 < 0.0001
HR hazard ratio, CI confidence interval, HAQ Health Assessment Questionnaire
Disability Score, NSAID non-steroidal anti-inflammatory drug, TNF tumour
necrosis factor
aRange 0–3, where higher scores indicate greater functional impairment
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